Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Ve...
Leadership
Thomas D. Zindrick J.D.
Chairman, CEO & President
Matthew Pulisic M.B.A.
CFO and Principal Financial & Accounting Officer
Joseph Cappello Ph.D.
Chief Technical Officer
Yong Yu Ph.D.
Chief Scientific Officer
Eric Groen J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
